Comparing when anti-PD-1 treatment starts in high-risk early-stage melanoma
Compares outcomes in melanoma patients given anti-PD-1 before or after surgery.
Plain-language title generated from the registry record
Registry title: NEOSENT: Early Anti-PD-1 Therapy In High-Risk Stage II Melanoma
Key facts
- Where
- São Paulo, BrazilSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with skin melanoma at stage IIB, IIC or stage III (N1c) who were treated in routine care. It only follows their outcomes.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Skin melanoma, stage IIB or IIC, or stage III (N1c), confirmed by tissue examination
Main reasons for not taking part
- Not enough clinical or follow-up data
- No informed consent given (for the prospective cohort)
Read by machine on 9 November 2026.
Where in Brazil
- AC Camargo Cancer CenterSão Paulo, BrazilTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- AC Camargo Cancer Center
- Trial code
- NCT07680699
- Record updated
- 2 July 2026
- Original description
This is an observational cohort study evaluating clinical and pathological outcomes in patients with high-risk stage II melanoma.Read full original descriptionShow less
NEOSENT - Early Anti-PD-1 Therapy In Patients With High-Risk Stage II Melanoma And/Or Microsatellitosis: An Ambispective Observational Cohort Study
This is an observational cohort study evaluating clinical and pathological outcomes in patients with high-risk stage II melanoma.
Patients are included after receiving treatment as part of routine clinical practice. Decisions about treatment, including whether to start anti-PD1 therapy before surgery, are made by the treating physician and are not influenced by the study.
The study compares outcomes between patients who started anti-PD1 therapy before surgery and those treated according to the usual timing in clinical practice.
No treatments are assigned as part of the study.
Inclusion: Adults (≥18 years) with histologically confirmed cutaneous melanoma stage IIB or IIC or stage III (N1c), managed in routine clinical practice.
Exclusion: Patients without sufficient clinical or follow-up data; Patients who do not provide informed consent (for prospective cohort).